BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments

Published on :

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.

Top Biotech Companies Hiring in Maryland: Summer 2022 Edition

Published on :

Here’s our Summer 2022 Roundup of top Maryland life sciences companies with more than 10 active job listings across a wide range of fields and experience levels. 

BD Completes Acquisition of Parata Systems

Published on :

Parata advances BD’s transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies. As a combined company, BD is positioned to offer a comprehensive set of technologies to the $600 million pharmacy automation market segment that is expected to grow approximately 10% annually to $1.5 billion in the U.S. alone over 10 years.

Cartesian, BD and REGENXBIO’s Ken Mills Take Home Top Honors at MTC’s Industry Awards Celebration

Published on :

The Maryland Tech Council, the largest technology and life science trade association in the state, announced the winners of its 2022 Industry Awards Thursday at the Bethesda North Marriott Hotel & Conference Center. The event, which honored companies, executives, students, and educators in 15 categories, marked the first in-person gathering for the Industry Awards Celebration since 2019. 

4 Baltimore Companies Driving Cancer Screening Technologies

Published on :

The cancer diagnostics market is surging, with an overall revenue growth expectation of hundreds of billions of dollars within the next eight years. The market is expected to grow to $257 billion by 2030, more than double the $124.9 billion valuation in 2021.

New BD Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Published on :

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new family of reagents that enables researchers to gain improved data resolution and greater insights from samples compared to traditional fluorochromes, made possible by their innovative development using novel dye technology and artificial intelligence (AI) guidance.